Abivax : ABX464 confirms its strong potential in ulcerative colitis and speculative interest in Abivax
>ABX464 has successfully achieved its phase IIb - Yesterday evening after market close, Abivax presented the top line results from its phase IIb trial on ABX464 in ulcerative colitis. These results were statistically significant on the primary endpoint: reduction in the modified Mayo score after eight weeks of induction and at each of the three doses tested. These promising results, notably with efficacy deemed impressive in patients that have failed to respond to bio...ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.